| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 85/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Bortezomib |
| Appearance | white Powder |
| Specification | 99% |
| Shelf life | 2 years when properly stored |
Function and Application
Bortezomib is a reversible inhibitor of the chymase-like activity of 26S protease in mammalian cells. In vitro tests demonstrated that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor models In vivo testing demonstrates that bortezomib delays tumor growth, including multiple myeloma. This product is used in the treatment of patients with multiple myeloma, the effectiveness is based on its efficiency.
Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells.
){kind=link}